## **ADVOCATE PHARMACY**Phone: 215-362-2479

535 South Broad Street Lansdale PA 19446

## **Rheumatoid Arthritis**

Prescription & Pharmacy Intake Form			
Provider Representative Phone	Date Needed Ship to ☐ Speci ☐ Prescriber's Of	alty Care Center	.e
PATIENT INFORMATIO	$\mathbf{N}$		
Patient Name:	DOB:	☐ Male ☐ Female	
Address:			
City: Phone # (Daytime):	State: Zip Code:		
Phone # (Daytime):	Phone # (Evening):	Case Manager:	
E-mail Address:	and back of card):	ase Manager.	-
ID#: Policy/Group	#: I	Phone #:	-
ID#: Policy/Group Name of Insured: Relationship to Patient: Self Ot	Employer:		
Relationship to Patient:	her:	☐ Patient is Eligible for Medicare	
Prescription Card: res no Carrie	or.	olicy/Group #:	-
Will there be access to anaphylactic medications a	nd oxygen at the administration site?		-
CLINICAL ASSESSMEN	<b>T</b> Medication	Dose/Directions/Freq Qty Refi	lls
☐ Patient is New to Therapy	Actemra® (tocilizumab)		
☐ Patient is Currently on Therapy	80 mg/4 mL Vial		
(Start Date:)	☐ 200 mg/10 mL Vial ☐ 400 mg/20 mL Vial		
☐ Physician Provides injection Training			
Injection/Infusion Date:	Cimzia® (certolizumab pegol)  ☐ 2x200 mg kit		
	Syringe Uial		
Primary ICD-9 Code and Condition:	Enbrel® (etanercept)		
0.1 160 0/6 10	25 mg Syringe 25 mg Vial		
Other ICD-9/ Conditions:	☐ 50 mg Syringe ☐ 50 mg Sure Click" Per <b>Humira® (adalimumab)</b>	1	
Joints Affected:	20 mg Syringe		
Number of Tender Joints:	☐ 40 mg Syringe ☐ 40mgPen		
Number of Swollen Joints:	Kineret® (anakinra)		
Current Weight: Date:	☐ 100 mg Syringe  Orencia® (abatacept)	<del>                                     </del>	
	(abatacept) (b) (4) 125 mg Prefilled Syringe		
☐ New Therapy Induction   Stop Date:	250 mg Vial		
☐ Therapy Change   Stop Date:	Remicade® (infliximab)		
☐ Therapy Continuation   Stop Date:	100 mg Vial	<del>                                     </del>	
Weeks Completed $\Box 0$ $\Box 2$ $\Box 4$ $\Box 6$	Rituxan® (rituximab)  100 mg Vial 500 mg Vial		
	Simponi® (golimumab)		
ESR & Date:	☐ 50 mg Syringe ☐ 50 mg Smartject		
CRP & Date:	Methotrexate - Can only be ordered as comb	ined therapy with one of above drugs	3
TB Results & Date:	2.5 mg Tablet	<del>                                     </del>	
Allergies:	Other		
PRESCRIBER INFORMA	ATION		
Prescriber's Name:	Practice/Facility Name:		
Address:	Office Contact		_
City: State:	Zip Code:		
Address:  City:  Phone #:  State:  Pax:  State Licenses #:  In order for a brand name product to be dispensed.	Best Ti	me to Call:	-
In order for a brand name product to be dispensed.	NYI#iNYI#iN	v" or "Rrand Medically	
In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state specific required language to prohibit substitution:			
I certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge.			
Prescriber's Signature Required: Date:			

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare, It bring-faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws.

IMPORTANT WARNING: This is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employer or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED If you have received this message in error, please notify us immediately.